Alvotech announced positive top-line results for AVT06, its biosimilar to Regeneron’s Eylea® (aflibercept). The study was a randomised, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea® in patients with neovascular (wet) age-related macular degeneration. The study met its primary endpoint, with results demonstrating therapeutic equivalence between AVT06 and Eylea®.
In May 2023, Alvotech and Polifarma announced an exclusive commercialisation agreement for AVT06 in Turkey.